The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy

The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy

Background Biologics are used for the treatment of patients with moderate to severe psoriasis. According to the recommendations of major global dermatological associations, patients who had not reported clinical symptoms or close contact with a confirmed/probable COVID-19 case in the last 14 days ca...

Full description

Bibliographic Details
Main Authors: Piotr Ciechanowicz, Klaudia Dopytalska, Agata Mikucka-Wituszyńska, Monika Dźwigała, Kacper Wiszniewski, Weronika Herniczek, Elżbieta Szymańska, Irena Walecka
Format: Article
Language:English
Published: Taylor & Francis Group 2022-04-01
Series:Journal of Dermatological Treatment
Subjects:
biologic treatment
psoriasis
covid-19
dermatology
anti-sars-cov-2 antibodies
Online Access:http://dx.doi.org/10.1080/09546634.2020.1861177

Internet

http://dx.doi.org/10.1080/09546634.2020.1861177

Similar Items